Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.53 |
| ▸ | CNR1 | P21554 | 11/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL249420 | 0.81 | CNR2 (0.62) | CNR2CNR1CYP2C9 | |
| SCHEMBL250363 | 0.79 | CNR2 (0.67) | CNR2CNR1CYP2C9 | |
| SCHEMBL249719 | 0.78 | CNR2 (0.66) | CNR2CNR1CYP2C9 | |
| SCHEMBL247887 | 0.75 | CNR2 (0.69) | CNR2CNR1CYP2C9 | |
| SCHEMBL249387 | 0.74 | CNR2 (0.71) | CNR2CNR1CYP2C9 | |
| SCHEMBL249803 | 0.74 | CNR2 (0.67) | CNR2CNR1CYP2C9 | |
| SCHEMBL247361 | 0.71 | CNR2 (1.00) | CNR2CNR1CYP2C9MEN1HTT | |
| SCHEMBL29362406 | 0.71 | CNR2 (1.00) | CNR2CNR1CYP2C9MEN1HTT | |
| Naphthoic Acid SCHEMBL27493013 | 0.70 | CNR2 (0.91) | CNR2CNR1CYP2C9MEN1HTT | |
| SCHEMBL27557505 | 0.68 | CNR2 (0.74) | CNR2CNR1CYP2C9MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |